We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Hutchmed (china) Limited | LSE:HCM | London | Ordinary Share | KYG4672N1198 | ORD USD0.10 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -4.00 | -1.59% | 247.00 | 81,385 | 16:35:08 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 247.00 | 249.00 | 260.00 | 247.00 | 249.00 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | USD 838M | USD 100.78M | USD - | - | 2.19B |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:35:08 | UT | 550 | 247.00 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 13/12/2024 | 10:04 | ALNC |  IN BRIEF: Hutchmed to get Takeda milestone payment |
| 13/12/2024 | 07:00 | UK RNS | Hutchmed (China) Limited HUTCHMED to Receive Milestone Payment from Takeda |
| 12/12/2024 | 07:00 | UK RNS | Hutchmed (China) Limited Breakthrough Therapy Designation in China |
| 03/12/2024 | 12:19 | ALNC | Hutchmed China injection approval could be a "paradigm shift" |
| 03/12/2024 | 10:00 | UK RNS | Hutchmed (China) Limited HUTCHMED and Innovent Announce ELUNATE Approval |
| 29/11/2024 | 08:30 | UK RNS | Hutchmed (China) Limited Total Voting Rights |
| 28/11/2024 | 10:32 | UK RNS | Hutchmed (China) Limited Continued Inclusion of ORPATHYS in China NRDL |
| 22/11/2024 | 10:00 | ALNC | Hutchmed to get payment from Takeda as Fruzaqla launched in Japan |
| 22/11/2024 | 07:00 | UK RNS | Hutchmed (China) Limited FRUZAQLA® Launched in Japan by Takeda |
| 20/11/2024 | 09:30 | UK RNS | Hutchmed (China) Limited Appointment of Independent Non-executive Director |
Hutchmed (china) (HCM) Share Charts1 Year Hutchmed (china) Chart |
|
1 Month Hutchmed (china) Chart |
Intraday Hutchmed (china) Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 13/12/2024 | 03:48 | (Chi-Med)Hutchinson China Meditech Limited | 4,095 |
| 25/3/2022 | 17:25 | Hutchison Chi-Med (HCM) One to Watch | 3 |
| 23/7/2018 | 09:55 | Hutchison Chi-Med (HCM) One to Watch on Monday | 1 |
| 13/6/2017 | 06:54 | Hutchison China Meditech- CHARTS AND DISCUSSION | 74 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 15/12/2024 08:20 by Hutchmed (china) Daily Update Hutchmed (china) Limited is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker HCM. The last closing price for Hutchmed (china) was 251p.Hutchmed (china) currently has 871,601,095 shares in issue. The market capitalisation of Hutchmed (china) is -. This morning HCM shares opened at 249p |
Posted at 12/12/2024 07:44 by lauders Good news again. Will it have any effect on the share price?Thursday, December 12, 2024: HUTCHMED (China) Limited (“HUTCHMEDR |
Posted at 09/12/2024 18:05 by fillipe HCM deserves more than the only +4p of the day, even after also recovering from a poor opening.Folks will surely catch on as the days go by, if they have the insight. f |
Posted at 29/11/2024 09:03 by shaker45 Just more sellers than reasons to buy. Markets looking toppy, more negative economic news from China. Probably nothing hcm specific. |
Posted at 22/11/2024 04:58 by lauders Good news from HCM today: HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in JapanThey also received a milestone payment from Takeda as a consequence. |
Posted at 12/11/2024 07:28 by 1jat AZ has reported Orpathys sales of $36m for the 9m to end September.This is consistent with the H1 run rate and FY sales should be close to $50m. The Savannah read out was the first item in the pipeline update. HCM has stated in the November corporate presentation that they expect AZ to submit the US NDA in 2024. They also mention accelerated approval, so we may see an approval late in 2025, both events are likely to trigger milestone payments followed by sales milestones and royalties in 2026. |
Posted at 17/10/2024 13:32 by 1jat Arguably both cash flow + and - lead to M&A - one as the major party and one as the minor party.There are a lot of biotechs in China and there are significant efficiencies possible across pipeline assets, sales and general administration. New money is hard to raise but mergers are likely to be encouraged by the mainland to build some national champions (globally China cos are not in the big pharma league - that should change). If CKHH is willing to back HCM issuing new equity or taking on some debt, then it should be possible for HCM to take the lead on some M&A deals and grow inorganically - that is how big Pharma got to be big rather than organic growth. Pre-commercial deals - will come with more uncertainty but the target will bring some cash and R&D capabilities. The main economies will come from pushing more volume through the factory and sales channels when the acquired products are approved. Commercial stage deals - Should generate value for both shareholders due to the large synergies…..ba I dont think HCM has the management to do a significant merger at the moment, so if they are to be on the front foot I would expect a new CEO and a strategy director to be appointed first. |
Posted at 16/10/2024 12:18 by dbadvn Won’t affect the share price. Market expects only positive clinical results , only reacts to the negative.It’s all about getting to cash flow positive. No more free money . Cash flow positive means survival and further growth. Not cash flow positive means takeover or merger. We will know which in the next 12 months or so. |
Posted at 30/7/2024 09:23 by 1jat As with all things M&A for HCM, it will come down to CKHH.China wants its raise its markets by encouraging firms to be more commercially oriented and provide value to owners….. Beigene is probably the most successful of its younger biotechs but is still small compared to big pharma. I expect there will be a wave of consolidation M&A within the chinese biotechs, and HCM will participate… The economics would appear compelling… The big news tomorrow will be Takeda’s sales in the US……they should have grown sales from the $50m in Q1 but by how much? Closer to $80m and it will look like the patient population is growing and could be much higher than the $200m pa currently penciled in by analysts. The rest of the year will be dominated by: 1 news of regulatory approvals with three reviews ongoing in China and one in Japan. 2 early sales in Europe by Takeda 3 AZ submitting Savolitinib for approval in the US. 4 Possible partner for Sovlep. |
Posted at 12/7/2024 06:35 by 1jat It seems that Goldman is in at CKHH and its reviews are proving a little leaky,Two stories in two days about the European Three mobile telecoms businesses and a second about CK Infrastructure. When they get to HCM it will be no surprise if they suggest M&A with other China biotech (I would not expect HCM to be the buyer as that would not generate immediate gains for CKHH). They should be having these discussions about reaising SH value from time to time. IMO CKHH has incubated HCM and may decide it does not have the resources/appetite to take it much further or the ability as a Board to oversee this specialist investment and therefore seeks to dilute its ownership. If they can get a proposal above hk$50 they will be obliged to seriously consider it. CK deals have often involved a mix of cash and listed shares followed by sell downs (eg recent mobile mast deal in Europe). No certainty of a deal emerging, but I feel there is change coming at CKHH and HCM may not be untouched by it. |
Posted at 14/11/2022 06:58 by lauders Nearly +20% in HK now! Come on HCM share price at least match that! |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
